Clinical Trial Spotlight: New Immunotherapy for MSS Advanced Colorectal Cancer
A new clinical trial is studying whether a combination of two immunotherapy drugs -botensilimab and balstilimab- can help people with advanced microsatellite stable (MSS) colorectal cancer live longer and improve their quality of life.
This study is for people whose colorectal cancer:
- Is MSS
- Cannot be removed by surgery
- Has progressed after all currently available treatments
At this stage, the usual approach is called best supportive care. This focuses on managing symptoms and maintaining comfort, but it does not stop the cancer from growing.
Researchers will compare this new treatment to best supportive care to see if it can:
- Help people live longer
- Improve quality of life
- Slow or shrink tumours
- Identify markers in the tumour or blood that may predict who benefits most
- Confirm the safety of these drugs
Immunotherapy works by helping the body’s immune system recognize and attack cancer cells. While immunotherapy has helped some people with colorectal cancer, MSS tumours usually do not respond well, making this research especially important.
Learn more about this study here:
This Phase 3 study aims to enroll more than 800 participants and is designed to address an important unmet need for people whose cancer no longer responds to standard therapies.
